Kwee L Yong

Title: Kwee L Yong: Innovator in Bi-specific T-cell Engagers

Introduction

Kwee L Yong is a prominent inventor based in London, GB. He has made significant contributions to the field of bi-specific T-cell engagers, particularly in the treatment of plasma-cell mediated diseases such as multiple myeloma. With a total of 6 patents to his name, Yong's work is at the forefront of innovative medical solutions.

Latest Patents

One of Kwee L Yong's latest patents is a bi-specific T-cell engager specific for B cell maturation antigen (BCMA). This invention provides a bi-specific molecule that includes a first domain binding BCMA, which comprises part of a proliferation-inducing ligand (APRIL), and a second domain capable of activating a T cell. This molecule is intended for use in treating plasma-cell mediated diseases, including multiple myeloma. Another significant patent involves a prognostic method for determining the prognosis of multiple myeloma by measuring BCMA expression in a sample. This method also includes treatments based on BCMA expression and kits for measuring BCMA levels.

Career Highlights

Throughout his career, Kwee L Yong has worked with notable companies such as UCL Business Plc and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed to his expertise in the field of biopharmaceutical innovations.

Collaborations

Kwee L Yong has collaborated with several professionals in his field, including Lydia Lee and Martin Pulé. These collaborations have likely enhanced his research and development efforts, leading to impactful innovations.

Conclusion

Kwee L Yong is a distinguished inventor whose work in bi-specific T-cell engagers and prognostic methods for multiple myeloma showcases his commitment to advancing medical science. His contributions are paving the way for new treatment options in the fight against cancer.